What is Eli Lilly doing about Zepbound shortage? Manufacturing expansions stabilize supply
•
4 min read
Following unprecedented demand, Eli Lilly resolved the widespread Zepbound shortage by investing billions in manufacturing expansions and strategic supply chain initiatives. This ultimately led the FDA to declare the tirzepatide supply issues resolved by December 2024.
